These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. Effect of Fluosol-DA (20%) on skin flap survival in rats. Ramasastry SS; Waterman P; Angel MF; Futrell JW Ann Plast Surg; 1985 Nov; 15(5):436-42. PubMed ID: 4083744 [TBL] [Abstract][Full Text] [Related]
65. Perfluorochemical-based artificial oxygen carrying red cell substitutes. Lane TA Transfus Sci; 1995 Mar; 16(1):19-31. PubMed ID: 10155703 [TBL] [Abstract][Full Text] [Related]
66. Fluorocarbons and the microcirculation. Faithfull NS; Fennema M; Van Alphen WA; Smith AR; Erdmann W; Essed CE; Kok A; Lapin R Acta Anaesthesiol Belg; 1984; 35 Suppl():69-78. PubMed ID: 6516761 [TBL] [Abstract][Full Text] [Related]
67. Effects of exchange transfusion with perfluorochemical emulsions on hepatic oxygen supply and blood flow in the rat. Bizot WB; Rink RD Experientia; 1985 Sep; 41(9):1127-9. PubMed ID: 4043318 [TBL] [Abstract][Full Text] [Related]
68. Limitation of myocardial reperfusion injury by intravenous perfluorochemicals. Role of neutrophil activation. Bajaj AK; Cobb MA; Virmani R; Gay JC; Light RT; Forman MB Circulation; 1989 Mar; 79(3):645-56. PubMed ID: 2537160 [TBL] [Abstract][Full Text] [Related]
69. Enhancement by perflusion emulsion (Oxygent) and carbogen breathing of the tumor growth delay of the FSaIIC fibrosarcoma after treatment with antitumor alkylating agents. Holden SA; Teicher BA; Ha C; Ara G; Herman TS Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):895-8. PubMed ID: 1391529 [TBL] [Abstract][Full Text] [Related]
70. Use of a whole blood substitute, Fluosol-DA 20%, after massive postpartum hemorrhage. Karn KE; Ogburn PL; Julian T; Cerra FB; Hammerschmidt DE; Vercellotti G Obstet Gynecol; 1985 Jan; 65(1):127-30. PubMed ID: 3871250 [TBL] [Abstract][Full Text] [Related]
71. Comparative studies with Fluosol, Dextran, their mixture, or autologous blood in experimental hypovolemic shock. Madjidi A; Beisbarth H; Frey R Prog Clin Biol Res; 1983; 122():391-7. PubMed ID: 6192451 [TBL] [Abstract][Full Text] [Related]
72. Effect of Fluosol-DA on radioimmunoassay results. Hammarstrom M; Mullins R; Sgoutas D Clin Chem; 1983 Jul; 29(7):1418-21. PubMed ID: 6861348 [TBL] [Abstract][Full Text] [Related]
73. Effect of perfluorochemical (Fluosol-DA) on infarct morphology in dogs. Kolodgie FD; Dawson AK; Forman MB; Virmani R Virchows Arch B Cell Pathol Incl Mol Pathol; 1985; 50(2):119-34. PubMed ID: 2868560 [TBL] [Abstract][Full Text] [Related]
74. The effects of fetal exchange transfusion with a red blood cell substitute. Ambrose A; Cefalo RC; Bowes WA Am J Obstet Gynecol; 1986 Mar; 154(3):667-74. PubMed ID: 3082209 [TBL] [Abstract][Full Text] [Related]
76. Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity. Teicher BA; Holden SA; Jacobs JL Cancer Res; 1987 Jan; 47(2):513-8. PubMed ID: 3098413 [TBL] [Abstract][Full Text] [Related]
77. Effect of Fluosol-DA 20% and oxygen on response of C57BL/6 mice to whole-body irradiation. Waldow SM; Lustig RA; Brass-Marlow EL; Nunno MP; Holst RJ; Wallner PE Int J Radiat Oncol Biol Phys; 1990 Sep; 19(3):665-8. PubMed ID: 2211213 [TBL] [Abstract][Full Text] [Related]
78. Which is the foreseeable clinical application of oxygen-carrying blood substitutes (fluorocarbons and hemoglobin solutions)? Which impact are they likely to have on the activity of blood services? Vox Sang; 1982 Feb; 42(2):97-109. PubMed ID: 7064434 [No Abstract] [Full Text] [Related]